Delcath Q1 2026 revenue $25M (+26% YoY); net loss $1.1M; guides FY rev at least $100M

DELCATH SYSTEMS, INC.

2026-Q1 EPS reported -$0.03 vs consensus -$0.09 ▲ beat (+66.1%)

Total revenue $25.0M, up 26% YoY; HEPZATO KIT revenue $23.3M (+29% YoY); CHEMOSAT $1.7M (flat).
Net loss of $1.1M vs net income $1.1M prior year; non-GAAP adjusted EBITDA $3.4M vs $7.6M.
Cash and investments $89.3M, no debt; repurchased 316,023 shares for $3.0M in Q1.
FY 2026 guidance: revenue at least $100M, gross margins 84-87%, positive adjusted EBITDA.
Active centers 29; CHOPIN Phase 2 trial published in The Lancet Oncology; ESMO guideline inclusion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

DELCATH SYSTEMS, INC. reported first quarter ended March 31, 2026 results: revenue $25.0 million, net income Net loss of $1.1 million. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $25.0 million
Net income: Net loss of $1.1 million
Guidance: raised
Result: reported results

Exact text from the filing

Total revenue of $25.0 million, compared with $19.8 million in the first quarter of 2025

View on SEC.gov

Browse all earnings releases →

DELCATH SYSTEMS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-031725

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.